AstraZeneca PLC (AZN)vsAzenta Inc (AZTA)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
AZTA
Azenta Inc
$23.13
-4.58%
HEALTHCARE · Cap: $1.07B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 9772% more annual revenue ($58.74B vs $595.03M). AZN leads profitability with a 17.4% profit margin vs -10.1%. AZTA appears more attractively valued with a PEG of 0.53. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
AZTA
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+42.6%
Fair Value
$53.08
Current Price
$23.13
$29.95 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Reasonable price relative to book value
Earnings expanding 8778.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Premium valuation, high expectations priced in
0.8% revenue growth
Smaller company, higher risk/reward
ROE of 1.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : AZTA
The strongest argument for AZTA centers on Price/Book, EPS Growth, Debt/Equity. PEG of 0.53 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : AZTA
The primary concerns for AZTA are P/E Ratio, Revenue Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a value stock while AZTA is a turnaround play — different risk/reward profiles.
AZTA carries more volatility with a beta of 1.47 — expect wider price swings.
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 57/100), backed by strong 17.4% margins. AZTA offers better value entry with a 42.6% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Azenta Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Azenta Inc. is a premier provider of sample management solutions and life science tools, dedicated to enhancing laboratory efficiencies for the biotechnology and pharmaceutical industries. By leveraging innovative automated solutions, comprehensive biorepository services, and advanced storage technologies, the company enables clients to accelerate drug discovery while adhering to stringent regulatory requirements. With a strong emphasis on cutting-edge technology and strategic partnerships, Azenta is well-positioned to seize growth opportunities in the expanding global life sciences market. Its commitment to advancing scientific research through sophisticated products further solidifies its competitive advantage in biobanking and sample management.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?